

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

Urquhart-Dykes & Lord  
Attn. AUSTIN, Hedley W.  
Alexandra House  
1 Alexandra Road  
Swansea, West Glamorgan  
UNITED KINGDOM

RECEIVED  
16 FEB 1998  
SAURQUHART-DYKES & LORD  
SWANSEA

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing  
(day/month/year)

13/02/1998

Applicant's or agent's file reference

P66367W0

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/GB 97/02790

International filing date

(day/month/year)

09/10/1997

Applicant

DUFF, Gordon et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicants's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Deborah Grandis

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

**"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

**Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

**Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>P66367W0</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 97/02790</b>	International filing date (day/month/year) <b>09/10/1997</b>	(Earliest) Priority Date (day/month/year) <b>10/10/1996</b>
Applicant <b>DUFF, Gordon et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☒ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☒ filed with the international application.

☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No.            ☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MANSFIELD J C ET AL.: "Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist" GASTROENTEROLOGY, vol. 106, 1994, pages 637-642, XP002053011 cited in the application see the whole document</p> <p>---</p> <p>-/--</p>	1-9

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 January 1998

Date of mailing of the international search report

13/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KO B C B ET AL.: "An (A-C)n dinucleotide repeat polymorphic marker at the 5'End of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients"</p> <p>DIABETES, vol. 44, 1995, pages 727-732, XP002053012 cited in the application see the whole document</p> <p>---</p>	1-9
P,X	<p>RICHARDSON P S R ET AL.: "Interleukin-1 gene polymorphisms are associated with sight-threatening diabetic retinopathy"</p> <p>INVESTIGATIVE OPHTHALMOLOGY, vol. 38, no. 4, 1997, page 3714 XP002053013 see the whole document</p> <p>-----</p>	1-9

# PATENT COOPERATION TREA

From the RECEIVING OFFICE

## PCT

### NOTIFICATION OF THE INTERNATIONAL APPLICATION NUMBER AND OF THE INTERNATIONAL FILING DATE

(PCT Rule 20.5(c))

To:

Urquhart-Dykes & Lord  
Alexandra House  
Alexandra Road  
Swansea

SA 1 SED

Date of mailing  
(day/month/year)

28 OCT 1997

Applicant's or agents's file reference  
P66367WO

#### IMPORTANT NOTIFICATION

International application No.  
PCT/GB97/02790

International filing date (day/month/year)  
09/10/1997

Priority date (day/month/year)  
10/10/1996

Applicant

Duff, Gordon et al

Title of the invention

Detecting Genetic Predisposition to Sight-Threatening Diabetic Retinopathy

1. The applicant is hereby notified that the international application has been accorded the international application number and the international filing date indicated above.

2. The applicant is further notified that the record copy of the international application:



was transmitted to the International Bureau on

28 OCT 1997



has not yet been transmitted to the International Bureau for the reason indicated below and a copy of this notification has been sent to the International Bureau\*:



because the necessary national security clearance has not yet been obtained.



because (reason to be specified):

\* The International Bureau monitors the transmittal of the record copy by the receiving Office and will notify the applicant (with Form PCT/IB/301) of its receipt. Should the record copy not have been received by the expiration of 14 months from the priority date, the International Bureau will notify the applicant (Rule 22.1(c)).

Name and mailing address of the receiving Office

The Patent Office  
Cardiff Road, Newport  
South Wales NP9 1RH

Facsimile No.

Authorized officer

Tracy Rogers.

Telephone No.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/15653</b> <b>(43) International Publication Date:</b> 16 April 1998 (16.04.98)
<b>(21) International Application Number:</b> PCT/GB97/02790 <b>(22) International Filing Date:</b> 9 October 1997 (09.10.97)  <b>(30) Priority Data:</b> 9621129.7 10 October 1996 (10.10.96) GB  <b>(71)(72) Applicants and Inventors:</b> DUFF, Gordon [GB/GB]; 18 Ashgate Road, Sheffield S10 3BZ (GB). RENNIE, Ian [GB/GB]; Church Lane House, Litton, Buxton, Derbyshire SK17 8QU (GB). RICHARDSON, Robert [GB/GB]; 1 Catchford View, Holme Park, Newbold, Chesterfield S41 8XE (GB).  <b>(74) Agent:</b> AUSTIN, Hedley, William; Urquhart-Dykes & Lord, Alexandra House, 1 Alexandra Road, Swansea SA1 5ED (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> DETECTING GENETIC PREDISPOSITION TO SIGHT-THREATENING DIABETIC RETINOPATHY  <b>(57) Abstract</b>  A method and kit for predicting increased risk of sight-threatening diabetic retinopathy which includes isolating genomic DNA from a sample from a diabetic patient. The genetic polymorphism pattern for the genes IL-1A, IL-1B and IL-1RN is then identified in the DNA. The identified pattern is compared with control patterns of known polymorphisms, and patients expressing a genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy are identified.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



- 1 -

**DETECTING GENETIC PREDISPOSITION  
TO SIGHT-THREATENING DIABETIC RETINOPATHY**

**BACKGROUND OF THE INVENTION**

5

**Technical Field of the Invention**

This invention relates to a method of detecting a predisposition to, and determining risk of, sight-threatening diabetic retinopathy. The invention also provides  
10 diagnostic kits for the assessment of risk of developing sight-threatening diabetic retinopathy.

**Description of the Prior Art**

15 Insulin dependent (Type I) and non-insulin dependent (Type II) diabetes mellitus are distinct diseases and patients with either form of the disease are at risk of developing microvascular and macrovascular complications such as neuropathy, nephropathy, retinopathy, atherosclerosis and cardiovascular disease. These complications are a major clinical burden in diabetes, but their pathogenesis is not well  
20 understood. Susceptibility to diabetic complications has been reported to be inherited independently of diabetes itself. [Sequist *et al.*, 1989; Ko *et al.*, 1995].

In the United States there are approximately 16 million diabetics, of which it is estimated that only half are diagnosed [CDC, 1995]. Retinal disease (retinopathy) is one of several complications of diabetes and is primarily the result of disruption of  
25 small blood vessels, such as capillary leakage, destruction or occlusion of capillaries leading to ischemia, and the uncontrolled growth of new vessels. In many situations, these changes affect the macula, which is the area of the retina that is specialized to color and visual acuity. All of these are consequences of retinal capillary closure or leakage and are not thought of as retinal inflammation.

30 Characteristic anatomical and physiological changes occur in the retinal circulation. Clinically, they may be classified as background changes, maculopathy and

- 2 -

proliferative disease. Any may be present at any level of retinopathy in the same patient, but not all cause visual loss.

Sight-threatening diabetic retinopathy is one of the most common complications of diabetes and is the most common cause of vision loss in the under 65 years age group in developed countries, as a result of non-resolving vitreous hemorrhage, traction retinal detachment or diabetic maculopathy. Sight-threatening diabetic retinopathy refers to diabetic complications affecting the retina that predictably lead to severe loss of vision. These changes include non-resolving vitreous hemorrhage, tractional retinal detachment, or retinal edema.

10       The following is a description of characteristic anatomical and physiological changes which occur in the retinal circulation in diabetes.

#### BACKGROUND DIABETIC RETINOPATHY (BDR)

15       Microaneurysms and intra-retinal microvascular abnormalities (IRMA) are found adjacent to areas of retinal capillary non-perfusion. Infarcts of the nerve fiber layer (sometimes called cotton-wool spots) and intra-retinal hemorrhages are also included in BDR, as are any areas where fluid swells the retina (retinal edema) which does NOT threaten the central vision. Background retinopathy is not associated with visual loss and does not therefore require treatment.

20

#### MACULOPATHY, INCLUDING CLINICALLY-SIGNIFICANT MACULAR EDEMA (CSME)

25       The macula lies at the posterior pole of the retina and is specialized for color and accurate vision (high visual acuity) at the fovea which lies centrally in the macula. It may be altered structurally by fluid or lipids collecting in the retina from localized or widespread leaking retinal capillaries (focal or diffuse maculopathy respectively) or by non-perfusion of para-foveal capillaries (ischemic maculopathy). Additionally, retinal traction, macular hemorrhage or macular hole formation will reduce visual acuity.

#### 30   PROLIFERATIVE DIABETIC RETINOPATHY (PDR)

As areas of capillary non-perfusion enlarge new vessels arise from the venous

- 3 -

circulation at the optic disc (NVD: new vessels at the disc) or from branch retinal veins (NVE: new vessels elsewhere).

Prior to the formation of frank new vessels, there is a pre-proliferative stage which is recognized clinically, as indicated by dilated, beaded retinal veins and signs of  
5 widespread retinal non-perfusion. Once the pre-proliferative stage has been identified, the risk of developing PDR in one year is 52% and of developing 'high-risk, PDR in five years is 60% (ETDRS12, 1991).

High-risk proliferative diabetic retinopathy is a characteristic appearance of the retina in which 50% of the patients will develop severe visual loss within 5 years.

10 Severe visual loss is a fall of 3 or more lines of visual acuity on the eye chart on two separate occasions 3 months apart. The characteristic retinal findings that would qualify for the diagnosis of high-risk PDR include one or more of the following:

1. New vessels at the disc (NVD) that involve at least 1/4 to 1/3 of the disc area. This is diagnosed by comparison to Standard Photograph  
15 10A of the Modified Airlee House Classification of Diabetic Retinopathy [DRS Report No. 7, 1981];
2. NVD less than 1/4 of the disc area if fresh vitreous hemorrhage is present; and
3. New vessels elsewhere (NVE) greater than or equal to 1/2 the  
20 disc area in size if fresh vitreous hemorrhage is present.

Appropriately timed laser treatment can reduce the two year incidence of severe visual loss (SVL) in 'high-risk, proliferative disease by 50% and the incidence of moderate visual loss (MVL) over two years in those with macular edema by 50%.

25 [DRS8, 1981; ETDRS1, 1985; ETDRS9, 1991]

#### ADVANCED DIABETIC RETINOPATHY

Initially, these new vessels leak and are fragile, with the resulting vitreous hemorrhage causing a sudden, often profound, loss of vision. The blood may resolve  
30 over the following weeks, but it may become organized into a dense opaque mass in the vitreous which does not resolve.

- 4 -

Fibrous tissue appears adjacent to these new vessels, which subsequently contracts, leading to tractional retinal detachments. New vessels may also grow across the iris and prevent fluid draining from the eye, causing rubeotic glaucoma.

## 5 EPIDEMIOLOGY

Approximately 16 million people in the United States have diabetes mellitus, of which 50% are diagnosed. Of these, 10-15% have insulin-dependent diabetes mellitus (Type I; IDDM) which is usually diagnosed before the age of 40 years of age. The  
10 majority have non-insulin dependent diabetes (Type II DM; NIDDM), some of which may be treated with insulin. From the Wisconsin epidemiological study of diabetic retinopathy, duration of diabetes is associated with increasing incidence of diabetic retinopathy [Klein *et al*, 1994]. Other risk factors include age less than 30 at diagnosis, being male, raised glycosylated hemoglobin (HbA<sub>1c</sub>), hypertension, hyperlipidemia,  
15 pregnancy and diabetic nephropathy.

Genetic testing is now possible (see United States Patents 4,582,788 and 5,110,920) for diseases associated with, or caused by, one to two genes, once the genes are identified, to determine the risk of a person carrying a given gene for the disease (see for example United States Patents 4,623,619, 4,801,531, 4,666,828 and  
20 5,268,267).

United States Patent Nos. 5,039,606 and 5,196,308, as well as Pociot *et al*. (1992) disclose methods of identifying people who are at risk for developing diabetes. However, these references do not provide methods of determining among diabetics those who are at risk for developing sight-threatening retinopathy. Ko *et al*. (1995) do  
25 provide a single factor, a polymorphic marker at the 5' end of the aldose reductase gene, that is associated with early onset of diabetic retinopathy in Chinese patients with NIDDM. However, this provides only one marker, which as shown in the Ko *et al*. reference does not identify all persons at risk. Additionally, the population studied is not the same ethnic population as found in the United States and much of Europe,  
30 therefore the data may not be completely applicable to US and European populations.

The pathogenesis of retinal complications from diabetes is not well understood.

- 5 -

Michelson (1940) however, proposed that as diabetes produces destruction of blood vessels in the retina, localized areas of ischemia develop resulting in the release of vasoproliferative factors. Research in recent years has focused on growth factors that stimulate vascular proliferation, especially basic fibroblast growth factor (BFGF) and vascular endothelial growth factor (VEGF) which are modulated by hypoxia. [Adamis *et al.*, 1994; Aiello *et al.*, 1994; Koyama *et al.*, 1994; Lowe *et al.*, 1995; Malecaze *et al.*, 1994; Mansfield *et al.*, 1994; Murata *et al.*, 1995; Peler *et al.*, 1995; Pfeiffer, 1995; Pfeiffer and Schatz, 1995]

Genetic testing (also called genetic screening or genotyping) can be defined broadly as the testing of nucleic acid of a patient in an analytical capacity to determine if a patient contains mutations (or alleles or polymorphism) that either cause or increase susceptibility to a disease state or are in "linkage disequilibrium" with the gene causing a disease state.

Linkage disequilibrium refers to the tendency of specific alleles to occur together more frequently than would be expected by chance. Alleles at given loci are in equilibrium if the frequency of any particular set of alleles (or haplotype) is the product of their individual population frequencies. The cause of disequilibrium is often unclear. It can be due to selection for certain allele combinations, or to a recent admixture of genetically heterogeneous populations. In addition, in the case of markers that very tightly link to a disease gene, an association of an allele (or a group of linked alleles) with the disease gene is expected if the disease mutation occurred in the recent past, so that sufficient time has not elapsed for equilibrium to be achieved through recombination events in that small chromosomal region.

The early detection of a predisposition to genetic diseases presents the best opportunity for medical intervention. Early genetic identification of risk may improve the prognosis for a patient through supervision and early intervention before the clinically detectable disorder occurs.

In cases where patients with similar symptoms are treated with variable success, sophisticated genetic testing can differentiate individual patients with subtle or undetectable differences and can lead to more suitable individual treatments. Early intervention may involve methods such as gene therapy or treatment with IL-1

- 6 -

modulators. With the development of genetic testing, it is now possible to identify gene mutations that indicate a propensity to develop disease, even when the disease is of polygenic origin. The number of diseases that can be identified by molecular biological methods continues to grow with increased understanding of the genetic basis of multifactorial disorders (*see, e.g.*, United States Patent Nos. 4,582,788; 5,110,920; 4,801,531; 4,666,828; and 5,268,267).

The IL-1 gene cluster is located on the long arm of human chromosome 2 (2q13) and contains at least the genes for IL-1 $\alpha$  (IL1A), IL-1 $\beta$  (IL1B), and the IL-1 receptor antagonist (IL1RN) within a region of 430 Kb (Nicklin, *et al.*, *Genomics* 19: 382-4 (1994)). The agonist molecules, IL-1 $\alpha$  and IL-1 $\beta$ , have potent pro-inflammatory activity and are at the head of many inflammatory cascades. Their actions, often via the induction of other cytokines such as IL-6 and IL-8, lead to activation and recruitment of leukocytes into damaged tissue, local production of vasoactive agents, fever response in the brain and the hepatic acute phase response. All three IL-1 molecules bind to type I and to type II IL-1 receptors, but only the type I receptor transduces a signal to the interior of the cell. In contrast, the type II receptor is shed from the cell membrane and acts as a decoy receptor. The receptor antagonist and the type II receptor, therefore, are both anti-inflammatory in their actions.

Certain alleles from the IL-1 gene cluster are known to be associated with particular disease states. For example, IL1RN allele 2 is associated with coronary artery disease, osteoporosis, nephropathy in diabetes mellitus (Blakemore, *et al.*, *Hum. Genet.* 97(3): 369-74 (1996)), alopecia areata (Cork, *et al.*, *J. Invest. Dermatol.* 104(5 Supp.): 15S-16S (1995)), Graves disease (Blakemore, *et al.*, *J. Clin. Endocrinol.* 80(1): 111-5 (1995)), systemic lupus erythematosus (Blakemore, *et al.*, *Arthritis Rheum.* 37: 1380-85 (1994)), lichen sclerosis (Clay, *et al.*, *Hum. Genet.* 94: 407-10 (1994)), and ulcerative colitis (Mansfield, *et al.*, *Gastroenterol.* 106(3): 637-42 (1994)). The IL1B(TaqI) allele 2 from marker +3953 of IL1B is also associated with psoriasis and insulin dependent diabetes in DR3/4 patients (di Giovine, *et al.*, *Cytokine* 7: 606 (1995); Pociot, *et al.*, *Eur J. Clin. Invest.* 22: 396-402 (1992)), and severe periodontal disease (Kornman, *et al.*, *J. Clin. Periodon.* 24:72 (1997)).

- 7 -

IL-1 has been shown to play a role in the pathogenesis of Type I diabetes (Dinarello, 1991; Todd, 1990, Mandrup-Poulsen *et al.*, 1993). There is no reported evidence to support a role for IL-1 in either proliferative diabetic retinopathy or maculopathy.

5           There has been a report on the purported role of cytokines in angiogenesis (Hu and Fan, 1995; Hu *et al.*, 1994). However, Franks *et al.* [1992] investigated IL-1, IL-6, IL-2 and TNF in vitreous and aqueous aspirates from eyes undergoing vitrectomy for the treatment of various eye diseases. IL-6 was observed in 6 samples from eyes with diabetic retinopathy (range = 5 to 480 pg/ml). Although IL-1 was detected in  
10 80% of all the samples investigated, concentrations of this cytokine greater than 3pg/ml were only observed in one specimens from eyes with uveitis (5 and 20 pg/ml, respectively) and two samples from eyes with diabetic retinopathy (3 and 31 pg/ml, respectively). TNF was present in 1 sample from eyes with diabetic retinopathy (4 pg/ml), and IL-2 was detected in 2 samples from eyes with diabetic retinopathy. The  
15 authors concluded that the cytokine presence indicated that a local inflammatory processes may be switched on during many eye diseases and may amplify the clinical signs. The authors did not suggest and their data does not show any primary role for cytokines in the clinical severity of retinopathy. These authors have not reported any follow-up to this observation, and literature searches revealed no other studies that  
20 examined cytokines in diabetic retinopathy. The focus in the literature has therefore remained that the dominant factor in controlling clinical outcome is mediated by glucose metabolic factors.

Genetic variation at the multiple loci controlling immune responses, particularly cytokines, has been a factor in determining susceptibility to diseases with inflammatory  
25 components. However, diabetic retinopathy is not an inflammatory condition. As discussed above given the tissue changes seen in retinopathy some local production of cytokines can be expected as was seen by Franks *et al.* [1992], but this is not an inflammatory condition.

It was therefore unexpected to find for a condition that is not primarily  
30 inflammatory in nature, both clinically-significant macular edema (maculopathy; CSME) and proliferative diabetic retinopathy (PDR), associated with cytokine gene

- 8 -

polymorphisms. The use of combinations of different cytokine polymorphisms indicates those patients who require closer observation and a more aggressive approach to retinopathy when it occurs.

Therefore, it was an objective of the present invention to determine genetic  
5 predictors for the risk of developing sight-threatening diabetic retinopathy. It would be useful to identify the genotypes and thereby identify diabetic patients who are susceptible to sight-threatening retinopathy so that early and aggressive monitoring and therapy can be initiated. Further, those patients who may be at higher risk by having the risk factor set forth in the Ko *et al.* paper and an additional predisposition based on  
10 the present invention need to be identified.



## SUMMARY OF THE INVENTION

According to the present invention, a method for predicting risk of sight-threatening diabetic retinopathy is disclosed. The method includes the steps of

5 isolating DNA from a patient and determining the DNA polymorphism pattern of the genes that code for IL-1 $\alpha$ , IL-1 $\beta$  and IL-1ra. The identified pattern from patients may be compared with controls of known DNA polymorphism patterns thereby identifying patients carrying a genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy. Patients so identified can then be treated more

10 aggressively in the early stages of diabetes to reduce or prevent the occurrence of severe retinopathy which leads to loss of sight.

The present invention further discloses a kit for the identification of a patient's genetic polymorphism pattern associated with increased risk of developing sight-threatening diabetic retinopathy. The kit includes DNA sample collecting means and

15 means for determining a genetic polymorphism pattern. The kit may also comprise control samples or standards so that a patient's risk of sight-threatening diabetic retinopathy can be determined.

- 10 -

**BRIEF DESCRIPTION OF THE DRAWINGS**

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description

5 when considered in connection with the accompanying drawings wherein:

FIGURE 1 is a graph of the length of time (survival) between diagnosis of diabetes and onset of proliferative diabetic retinopathy (PDR), as determined by time to first laser treatment for patients with either Type I or Type II diabetes, wherein patients with two copies of IL-1RN allele 2 (□) are compared with those having at most one  
10 copy of IL-1RN allele 2 (○); and

FIGURE 2 is a graph of the length of time (survival) between diagnosis of diabetes and onset of diabetic maculopathy, as determined by time to first laser treatment for patients with either Type I or Type II diabetes, wherein patients with a genotype at IL-1A (-889) and IL-1B (-511) have a combined number of copies of rarer  
15 alleles (allele 2) of three or more (□) are compared with patients with fewer than three copies (○) of the rarer alleles (allele 2) of IL-1A and IL-1B.

- 11 -

**DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

According to the present invention, diabetic patients without overt retinopathy are identified as having a genetic predisposition for sight-threatening retinopathy by  
5 detecting the presence of specific DNA polymorphisms in the gene sequences that code for IL- $1\alpha$ , IL- $1\beta$  and IL- $1\alpha$  as set forth herein below.

A "retinopathy" is defined generally as any disease of the retina. Briefly, diabetic retinopathy is one of the most common complications of diabetes as a result of non-resolving vitreous hemorrhage, traction retinal detachment or diabetic  
10 maculopathy. All of these are consequences of retinal capillary closure or leakage. "Sight-threatening diabetic retinopathy" refers to diabetic complications affecting the retina that predictably lead to severe loss of vision. Retinal disease is one of several complications of diabetes and is primarily the result of disruption of small blood vessels and the uncontrolled growth of new vessels. In some situations, these changes affect  
15 the macula, which is the area of the retina that is specialized to color and visual acuity.

The term "marker," as used herein, refers to a specific site in the genome which exhibits sequence variations between individuals. For example, herein described is a marker for identification of propensity to develop sight-threatening diabetic retinopathy.

20 The term "allele" refers to the different sequence variants found at given markers. The sequence variants may be single or multiple base changes, including insertions, deletions or substitutions or may be variable number of sequence repeats and the like.

The term "linkage disequilibrium" refers to the co-inheritance of two alleles at  
25 frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given control population. The expected frequency of occurrence of two alleles that are inherited independently is the frequency of the first allele multiplied by the frequency of the second allele. Alleles that co-occur at expected frequencies are said to be in 'linkage equilibrium.'

30 The term "haplotype" is a set of alleles that are inherited together as a group (are in linkage disequilibrium). As used herein, haplotype is defined to include those

- 12 -

haplotypes that occur at statistically significant levels ( $p_{\text{corr}} \leq 0.05$ ). As used herein the phrase "an IL-1 haplotype" refers to a haplotype in the IL-1 loci.

As used herein, the process of "detecting alleles" is variously described as "genotyping, determining or identifying an allele or polymorphism," or any similar  
5 phrase. The allele actually detected might be a disease-causing mutation, or a mutation that is in linkage disequilibrium with a disease-causing mutation. It will be manifest in the genomic DNA of a patient, but may also be detectable from RNA or protein sequences transcribed or translated from this region.

By "propensity," "predisposition" or "susceptibility" for disease what is meant  
10 is that certain alleles are hereby discovered to be "associated" with sight-threatening diabetic retinopathy. They are thus over represented in frequency in individuals with disease as compared to healthy individuals.

The term "polymorphism" as used herein refers to variation in the gene sequence. The polymorphisms can be those variations (DNA sequence differences)  
15 which are generally found between individuals or different ethnic groups and geographic locations which, while having a different sequence, produce functionally equivalent gene products. The term can also refer to variants in the sequence which can lead to gene products that are not functionally equivalent. Polymorphisms also encompass variations which can be classified as alleles and/or mutations which can  
20 produce gene products which may have an altered function. Polymorphisms also encompass variations which can be classified as alleles and/or mutations which either produce no gene product or an inactive gene product or an active gene product produced at an abnormal rate or in an inappropriate tissue or in response to an inappropriate stimulus. Further, the term is also used interchangeably with allele as  
25 appropriate.

The invention is directed to a method of predicting the propensity or predisposition of a patient to sight-threatening diabetic retinopathy by genotyping the patient's DNA at an IL gene cluster. The patient's genotype may be compared with a control sample that contains one or more alleles from an IL haplotype, such as but not  
30 limited to the IL-1A, IL-1B and/or IL-1RN marker DNA is extracted from a suitable specimen using techniques known to those skilled in the art. Suitable specimens are

- 13 -

those which comprise DNA and include, but are not limited to blood, buccal swabs and saliva.

In a preferred embodiment, the DNA will be obtained from blood cells collected from a finger prick of the patient with the blood collected on absorbent paper.

- 5 In a further preferred embodiment, the blood will be collected on an AmpliCard™ (University of Sheffield, Section of Molecular Medicine, Royal Hallamshire Hospital, Sheffield, England S10 2JF). The DNA is then isolated from the dried blood spots and then target sequences amplified using appropriate techniques.

- 10 Techniques for determining the presence or absence of the particular allele of interest may be nucleic acid techniques based on size or sequence, such as restriction fragment length polymorphism (RFLP), nucleic acid sequencing, or hybridization. These techniques may also comprise the step of amplifying the nucleic acid before analysis. Amplification techniques are known to those of skill in the art and include cloning, polymerase chain reaction (PCR), polymerase chain reaction of specific alleles  
15 (PASA), ligase chain reaction, nested polymerase chain reaction, and the like. Amplification products may be assayed in a variety of ways, including size analysis, restriction digestion followed by size analysis, detecting specific tagged oligonucleotide primers in the reaction products, allele-specific oligonucleotide (ASO) hybridization, sequencing, hybridization, and the like.

- 20 PCR based detection means include multiplex amplification of a plurality of markers simultaneously. For example, it is well known in the art to select PCR primers to generate PCR products that do not overlap in size and can be analyzed simultaneously. Alternatively, it is possible to amplify different markers with primers that are differentially labeled and thus can each be detected. Other techniques are  
25 known in the art to allow multiplex analyses of a plurality of markers.

- The amplified DNA sequences from the template DNA are then analyzed using restriction enzymes to determine the genetic polymorphism present in the amplified sequences and thereby provide a genetic polymorphism profile of the patient. Allele detection techniques may be protein based if a particular allele produces a protein with  
30 an amino acid variant. For example, epitopes specific for the amino acid variant can be detected with monoclonal antibodies. Likewise, it is possible to detect alleles if they

- 14 -

are present in processed RNA by techniques that are known in the art.

Another embodiment of the invention is directed to kits for detecting a propensity for enhanced risk of sight-threatening diabetic retinopathy in a patient. The kits can be used pre- or post-symptomatically or prenatally. The kit may comprise one or more oligonucleotide capable of hybridizing to nucleic acid from the IL gene cluster. A number of assay formats are useful for genotyping using the provided oligonucleotide. The most common formats involve nucleic acid binding, such binding to filters, beads, or microtiter plates and the like. Techniques may include dot blots, RNA blots, DNA blots, PCR, RFLP, and the like.

10       The oligonucleotide may be a variety of natural and synthetic compositions such as synthetic oligonucleotide, restriction fragments, cDNAs, synthetic PNAs, and the like. The assay may also employ labeled oligonucleotide to allow ease of identification in the assays. Examples of labels which may be employed include radiolabels, enzymes, fluorescent compounds, streptavidin, avidin, biotin, magnetic  
15       moieties, metal binding moieties, antigen or antibody moieties, and the like. Oligonucleotides useful in the present invention for identifying the IL marker include those listed below in Sequence ID Nos 1-10 and in the examples.

      The method of the present invention therefore provides for identifying diabetic patients expressing a multiple genetic polymorphism pattern for cytokine genes  
20       associated with risk of sight-threatening diabetic retinopathy and who would therefore have an increased risk of sight-threatening diabetic retinopathy. Control patterns may be run concurrently. However, it is anticipated that the method may be conducted without concurrent testing of control specimens. From this is determined the number of polymorphisms carried by the diabetic patient that are associated with diabetic  
25       retinopathy risk. This allows a determination of the overall risk factor for sight-threatening diabetic retinopathy.

      The interleukin-1 (IL-1) gene cluster comprises the three cytokine genes (IL-1A, IL-1B and IL-1RN) that have been physically mapped to a 430 kb fragment of DNA on the long arm of human chromosome 2 [Nicklin *et al.*, 1994]. Applicants have  
30       described and characterized polymorphisms in these genes, which are associated with several autoimmune diseases (McDowell *et al.*, 1995; Clay *et al.*, 1994; Cork *et al.*,

- 15 -

1993; Blakemore et al., 1994; Blakemore 1996; Tarlow et al., 1994).

A specific polymorphism in the gene for IL1ra, one of the molecules that blocks IL-1 activity, appears to protect patients from the development of proliferative diabetic retinopathy (PDR; Figure 1 and Table 1). Patients were screened for the presence of IL-1RN allele 1 or IL-1RN allele 2 and it was found that patients with a genotype of two copies of allele 2 were almost completely protected from PDR.

TABLE 1  
PROLIFERATIVE DIABETIC RETINOPATHY

GENOTYPE	NO PDR	PDR	TOTAL
IL-1RN 2, * OR 1, *	366	93	459
IL-1RN 2,2	42	2	44
TOTAL:	408	95	503

\* allele other than 2.

$\chi^2$ : P=0.008      CI:1.27-22.5  
OR: 5.34      KAPLAN-MEIER p=0.0227

Interestingly, a specific genotype combination of polymorphisms in the genes for IL-1A and IL-1B appears to predispose diabetic patients to the development of maculopathy occurring much earlier in the disease (Figure 2 and Table 2).

- 16 -

TABLE 2A  
MACULOPATHY

GENOTYPE	NO MAC	MAC	TOTAL
IL-1A + IL-1B Allele 2 < 3	389	59	448
IL-1A + IL-1B Allele 2 ≥ 3	30	16	46
TOTAL:	419	75	494

 $\chi^2$ : P=0.0001

CI: 1.81-6.84

OR: 3.52

KAPLAN-MEIER

p=0.0017

Each locus has two alleles, allele 1 and allele 2, with allele 2 being the less common (rarer) allele at both loci. Patients were evaluated for their allelic genotype at these loci and patients with three or four copies of allele 2 (at the combined loci) were significantly more susceptible to maculopathy, having an Odds Ratio of 3.52. The genotypes that predispose to maculopathy include:

<u>IL-1A (-889)</u>	+	<u>IL-1B (-511)</u>
1,2	+	2,2
2,2	+	1,2
2,2	+	2,2



- 17 -

## B. IL-1RN 2,2 PATIENTS REMOVED

GENOTYPE	NO MAC	MAC	TOTAL
IL-1A + IL-1B Allele 2 < 3	360	55	415
IL-1A + IL-1B Allele 2 ≥ 3	26	16	42
TOTAL:	386	71	457

 $\chi^2$ : P=0.0001

CI:2.0-8.01

OR: 4.03

KAPLAN-MEIER p=0.001

10

Of further interest is the determination that if diabetic patients with the above genotypes are also screened for their IL-1RN genotype and patients having an IL-1RN 2,2 genotype are removed, the odds ratio is increased to 4.0. This supports the role of IL-1RN as a marker for protection against maculopathy.

15

Oligonucleotide DNA primers that target the specific polymorphic DNA region within the genes of interest are prepared so that in the PCR reaction amplification of the target sequences is achieved. This embodiment has the advantage of requiring only a small amount of blood and avoids the necessity for venipuncture or a tissue biopsy. Alternatively, in another embodiment buccal smears are used. Other means for collecting DNA and determining polymorphism patterns as known in the art can be used.

20

The primers that were used in the Examples are set forth in SEQ ID Nos:1-6. Other primers can be used that can be determined as known in the art. For example, the following additional primers can be used:

25

PRIMERS FOR IL-1A (-889)

- a) 5' - TGT TCTA CCA CCTG AAC TAGG C - 3' (-967/-945) (SEQ ID No:7)
- 5' - TTA CATA TGA GCCT TCC ATG - 3' (-888/-869) (SEQ ID No:8)
- 30 b) 5' - AAG CTT GTT CTA CCA CCT GAA CTA GGC - 3' (SEQ ID No:9)
- 5' - TTA CAT ATG AGC CTT CCA TG-3' (SEQ ID No:10)

- 18 -

The amplified DNA sequences from the template DNA may then analyzed using restriction enzymes to determine the genetic polymorphisms present in the amplified sequences and thereby provide a genetic polymorphism profile of the patient.

One of the primary components of the inflammatory and other immune responses is cytokine production. Cytokines are peptide/protein immunomodulators that are produced by tissue cells and activated immune cells including thymus-derived T lymphocytes (T-cells), B lymphocytes and monocyte/macrophages. The cytokines include interleukins (IL-1 through IL-17), colony stimulating factors (CSFs) for granulocytes and/or macrophages (CSF-G, CSF-M, CSF-GM), tumor necrosis factors (TNFs  $\alpha$  &  $\beta$ ), and interferons (IFN  $\alpha$ ,  $\beta$  &  $\gamma$ ). The basic activity of IL-1 includes the combined activities of IL-1 $\alpha$ , IL-1 $\beta$  and IL-1 receptor antagonist (IL-1ra). (For a review, see Duff, 1993; and Basic and Clinical Immunology, 8th Ed., 1994, Stites, Terr & Parslow, editors, Chapter 9, pgs. 105-123.). Association of a single cytokine polymorphism and autoimmune disease states have been found as, for example, in Systemic Lupus Erythematosus, Ulcerative Colitis and Juvenile rheumatoid arthritis [Mansfield et al., 1994; Verjans et al., 1992; Blakemore et al., 1994; McGuire et al., 1994; McDowell et al., 1995].

Specific polymorphisms in IL-1A, IL-1B and IL-1RN are associated with increased risk of sight-threatening diabetic retinopathy even though a retinopathy has not traditionally been thought of as an inflammatory condition. The polymorphisms for these genes are as follows:

IL-1A: (chromosome 2 at 2q12-14)

The alleles of a bi-allelic polymorphism of a single base variation (C/T) at -889 are identified by allele-specific cleavage using a restriction enzyme. The gene is designated IL-1A while the product (cytokine) is designated IL-1 $\alpha$ . Allele 1 is C and allele 2 is T at base -889. The full restriction enzyme recognition site is created by introducing a partial site by mutation in the PCR reaction with a modified primer sequence. The site is completed by the sequence of one of the alleles of the polymorphism. After restriction enzyme digestion by *NcoI* of the products of the PCR reaction, the DNA is separated electrophoretically by size.

- 19 -

From this gel (or a southern blot of it probed with a radioactive internal DNA sequence) the alleles of the polymorphism are identified. The uncut fragment (larger) is the rarer allele (allele 2) in Northern European populations.

5 IL-1B: (chromosome 2; 2q12-14)

Two bi-allelic polymorphisms can be typed in two different PCR products using allele-specific cleavage at naturally-occurring sites in the alleles. Allele identification is by size of fragment after restriction digestion and separation in an agarose gel. The gene is designated IL-1B while the product (cytokine) is designated IL-1 $\beta$ . The sites  
10 are single base variations (C/T) at -511 (referred to as IL-1B (-511)) and at +3953 (referred to as IL-1B (+3953)) and are identified by allele-specific cleavage using restriction enzymes. For each polymorphism allele 1 is C and allele 2 is T, with allele 2 being the rarer allele.

15 IL-1RN: (chromosome 2; 2q12-14)

Five (5) alleles of the intron 2 variable number tandem repeat (VNTR) polymorphism can be typed by electrophoretic sizing by the number of repeats present. PCR is used to amplify the VNTR region by using primers based on the flanking DNA sequences of the VNTR. The gene is designated IL-1RN while the product (cytokine)  
20 is designated IL-1ra. Allele 1 contains four repeats and the PCR product is 412 bp; Allele 2 contains two repeats and the PCR product is 240 bp; Allele 3 contains five repeats and is 498 bp; Allele 4 contains three repeats and is 326 bp; and Allele 5 contains six repeats and is 584 bp.

The patient's cytokine polymorphism profile, i.e., the different alleles present at  
25 each of the typed loci (genotype), may be compared with control standards to allow identification of the alleles. In one embodiment, controls are provided that are ethnically and gender matched to accommodate genetic variations within subpopulations.

An odds ratio (approximate relative risk) has been derived to test the  
30 association between allelic polymorphism pattern (genotype) at these specific loci and development of disease. This provides predictive information that is used in the clinical

- 20 -

management.

The above discussion provides a factual basis for a method and for a kit for the identification of a patient's genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy. The identification of those at risk for severe disease allows preventive measures to be initiated prior to disease onset. Further, those patients who have multiple risk factors, that is risk factors in addition to those determined by the present invention, can be particularly monitored since their risk is extremely high. The methods used with and the utility of the present invention can be shown by the following example.

#### 10 EXAMPLE

##### General Methods

Reactions and manipulations involving nucleic acid techniques, unless stated otherwise, were performed as generally described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press; polymerase chain reaction (PCR) was carried out generally as described in PCR Protocols: *A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990) and methodology as generally described in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and McDowell et al., 1995, these cited references incorporated herein by reference.

Enzymes used in PCR were from GIBCO BRL, thermocyclers were either Perkin-Elmer or Biometra. Restriction enzymes *NcoI* and *TaqI* were from Promega (US). Restriction enzymes *AvaI* and *Bsu36I* were from NEB (US). Other reagents were from Gibco (UK).

25

##### Statistical Analysis

$X^2$  analysis was used. Where required the analyses were performed with the SAS statistical package. The Odds Ratio (relative risk) is calculated from a 2x2 contingency table as described by Woolf [1955] as shown below. The following formula:  $(A \times D)/(C \times B)$  is used to calculate the Odds Ratio.

30

- 21 -

Sample Contingency Table

	Genotype of Interest	Phenotype 1	Phenotype 2
	Present	A	B
5	Absent	C	D

For each cytokine, the probabilities of (i) having two copies of the rarer polymorphism or (ii) the total number of copies of the rarer polymorphism in the disease groups (i.e. those with PDR and CSME) compared to the control population was determined using a  $X^2$  test and calculating the odds ratio.

Multivariate analysis for combinations of cytokine gene polymorphisms was performed using a factorial analysis of variance (ANOVA) for the likelihood of developing PDR or CSME. The interval to the onset of PDR or CSME was determined using Kaplan-Meier univariate analysis for each cytokine and a Cox proportional hazard model (multivariate regression analysis) for interactions between different cytokines and the patients sex and age at diagnosis was constructed. For the Cox regression, a forward stepwise procedure was used on the basis of the likelihood-ratio statistic (probability for entry of 0.05 or less and of 0.10 or more for removal).

#### Genotyping

Genetic polymorphisms associated with sight-threatening diabetic retinopathy in adults were determined using the protocol of McDowell et al. [1995]. PCR conditions for each polymorphism were performed as previously described [Di Giovine et al., 1992; Tarlow et al., 1994; Pociot et al., 1992] and as detailed herein below. The different alleles were identified on gels, as indicated, and stained with 0.2µg/ml ethidium bromide and visualized under UV light. Negative controls without DNA were performed in each experiment.

#### 30 DNA preparation

DNA was extracted from whole blood using a modification of the salt-out method (Nucleon II™, Scotlab, UK).

- 22 -

PCR Amplification and Product Sizing Protocols for Selected Alleles

The reactions for all the polymorphisms were carried out in 50 µl reactions comprising 10 reaction buffer (final concentration 1mM Tris-HCl, 5 mM KCl, dNTPs (final concentration 0.8mM, *Taq* polymerase (1.25U) and W-1 detergent (0.05%) The MgCl<sub>2</sub> and primer concentrations varied for each polymorphism.

IL-1A (-889): The single base variation (C/T) polymorphism at IL-1A base - 889 was identified as follows:

**SCREENING:** PCR amplification of genomic templates. One mismatch inserted in a primer to complete an *NcoI* site if C is available at -889.

**10 PRIMERS:** The following primers were used in the Example and were produced in an ABI DNA synthesizer based on the genomic sequences [Furutani et al., 1986; GENBANK X03833].

5' AAG CTT GTT CTA CCA CCT GAA CTA GGC 3' (-967/-945) (SEQ ID No:1)

5' GTA CCT TCC GAG TAT ACA TT 3' (-888/-869) (SEQ ID No:2)

15

**PCR CONDITIONS:**

Primers final concentration of 1.0µM and 1.5mM final concentration of MgCl<sub>2</sub>.

**20** 1 cycle [96°C (1 minute)];  
35 cycles [94°C (1 minute), 46°C (1 minute), 74°C (1 minute)];  
1 cycle [72°C (5 minutes)].

**25 RESTRICTION ENZYME DIGESTION:** Digestion was with 6 Units per 5µl reaction mixture of *NcoI* at 37°C, overnight. Sizing was by 6%. PAGE (150V for 2.5 hours)

**PREDICTED RESULTS FROM DIGESTION:**

Allele 1 (C) ; *NcoI* digestion of PCR products of allele 1 will yield 83 and 16 basepair (bp) fragments.

**30** Allele 2 (T) *NcoI* digestion of PCR products of allele 2 (rarer allele) will be ineffective and yield a 99 basepair (bp) product.

- 23 -

**IL-1B (-511):** The single base variation (C/T) polymorphism at IL-1B base - (-511) was identified as follows:

**SCREENING:** PCR amplification of genomic templates. The single base variation completes an *AvaI* site on allele 1 (C), a *Bsu36I* site on allele 2 (T).

5

**PRIMERS:** The following primers were produced in an ABI DNA synthesizer based on the genomic sequences [Clark et al., 1986; GENBANK X04500].

5' TGG CAT TGA TCT GGT TCA TC 3' (-702/-682) (SEQ ID No:3)

5' GTT TAG GAA TCT TCC CAC TT 3' (-417/-398) (SEQ ID No:4)

10

**PCR CONDITIONS:**

Primers final concentration of 1.0 mM and 2.5mM final concentration of  $MgCl_2$ .

1 cycle [95°C (2 minutes)];

15 35 cycles [95°C (1 minute), 53°C (1 minute), 74°C (1 minute)];

1 cycle [74°C (4 minutes)].

**RESTRICTION ENZYME DIGESTION:** Digestion was with 3 Units per 30  $\mu$ l reaction mixture of *AvaI* and at 37°C, for 8 hours or overnight. Sizing was by electrophoretic mobility (8% PAGE at 150V for 2.5 hours).

20

**PREDICTED RESULTS FROM DIGESTION:**

Allele 1 (C) *AvaI* digestion of PCR products of allele 1 will yield 190 and 114 bp fragments. *Bsu36I* digestion of PCR products of allele 1 will be ineffective and yield a 304 bp product.

25 Allele 2 (T) *AvaI* digestion of PCR products of allele 2 (rarer allele) will be ineffective and yield a 304 bp product. *Bsu36I* digestion of PCR products of allele 2 will yield 190 and 114 bp fragments.

**IL-1RN:** Intron 2 of the IL-1RN gene contains a VNTR region and the polymorphism of this region gives rise to five (5) alleles as described herein above which were identified as follows:

30

- 24 -

SCREENING: PCR amplification of genomic templates followed by assessment of the size of the product after separation on agarose gels.

PRIMERS: The following primers were produced in an ABI DNA synthesizer based on the genomic sequences:

5' CTCAGCAACACTCCTAT 3' (SEQ ID No:5)

5' TCCTGGTCTGCAGGTAA 3' (SEQ ID No:6)

PCR CONDITIONS:

10 [There was text missing here in the original UK filing] with 1.75mM (final concentration) MgCl<sub>2</sub> and cycling protocol of 1 cycle at 96°C for 1 minute; 30 cycles of [94°C (1 minute), 60°C (1 minute), 70°C (1 minute)]; and 1 cycle at 70°C for 2 minutes.

15 SIZING

Electrophoresis on 2% agarose gel at 90V for 45 minutes.

PREDICTED RESULTS FROM SIZING:

Allele 1 contains four repeats and is 412 bp;  
20 Allele 2 contains two repeats and is 240 bp;  
Allele 3 contains five repeats and is 498 bp;  
Allele 4 contains three repeats and is 326 bp; and  
Allele 5 contains six repeats and is 584 bp.

Although there are five known alleles at the IL-1RN locus alleles 3, 4 and 5 are  
25 rare. The predicted results are based on the assumption that the polymorphisms are and exact multiple of an 86 basepair repeat +68 basepairs as described above. However, as is known in the art, the size may vary slightly due to reading errors and the like. One skilled in the art of would know and compensate for such errors.

30 PATIENTS

Data is available on 539 patients with diabetes who attended the Diabetic clinic



- 25 -

and were enrolled into the study (Table 3). After informed consent was received, a sample of blood was obtained and the polymorphisms for cytokine genes IL-1A (-889), IL-1B (-511) and IL-1RN were determined as described.

TABLE 3

5                                      **Mean Age At Diagnosis of Diabetes**

		<u>M+F</u>	<u>M</u>	<u>F</u>
	<u>Combined Type I + Type II</u>			
10	CONTROLS	24.4	24.7	24.5
	CSME	36.3	35.3	37.3
	PDR	27.6	27.9	27.1
	<u>Type I Only</u>			
15	CONTROLS	23.0	23.5	22.5
	CSME	24.0	25.4	20.9
	PDR	18.1	19.6	14.9
	<u>Type II Only</u>			
20	CONTROLS	51.9	49.8	56.5
	CSME	49.5	50.8	48.2
	PDR	50.2	51.2	48.2

25                                      Of the patients in the study, 166 stated that they had received laser treatment for retinopathy, of which ten were found not to have had laser treatment and case-notes were not available on nine. The number of patients who denied laser treatment but who had, (i.e. false negatives) could not be determined. The remaining 383 served  
30 as a control population of diabetics.

DATA COLLECTED

The case-notes from the diabetic clinic were reviewed to obtain:

35                                      The date of birth and sex of the patient, the date of diagnosis of diabetes and age at diagnosis, if they had Type I or Type II diabetes and the presence of nephropathy or neuropathy.

The case-notes from visits to the Ophthalmology Clinic were reviewed and at

- 26 -

each attendance the following details were obtained to record:

Date of attendance, interval from diagnosis of diabetes, Snellen visual acuity, presence of background retinopathy, pre-proliferative, proliferative and advanced diabetic retinopathy, and the presence of vitreous hemorrhage. The PDR was noted as  
5 NVD, NVE or both. The presence of maculopathy was noted and recorded as focal, diffuse, ischemic or mixed.

### RESULTS

Changes in the frequencies of cytokine gene polymorphisms are associated with  
10 proliferative diabetic retinopathy (PDR) and maculopathy. The interval from diagnosis of diabetes to the onset of sight-threatening retinopathy was associated with specific cytokine polymorphisms, either singly or in combination.

All patients were analyzed together, then according to the type of diabetes. Overall, 77 patients in the study developed maculopathy, 46 males and 31 females. Of  
15 the 77 who developed maculopathy, 40 were Type I diabetics who developed maculopathy and 37 were Type II diabetics. Overall 96 diabetic patients developed PDR, 69 with Type I diabetes and 27 with Type II diabetes. Average age at diagnosis of diabetes is set forth in Table 3. There was a mean of 220.9 months follow-up (range 0-1065 months) for each patient with no significant differences between the sexes in  
20 length of follow up.

#### CLINICALLY-SIGNIFICANT MACULAR OEDEMA (CSME)

The mean interval to the onset of maculopathy was 166 months (0-840m), 224m (0-516m) for Type I and 110.1m (I-291m) for Type II diabetics.

25 Genotypes were analyzed for relationship to the survival time from diagnosis of diabetes to treatment for proliferative diabetic retinopathy, with the following findings. Few diabetics with two copies of allele 2 at the IL-1RN locus developed PDR even 50 years after diagnosis of diabetes. However, up to 50% of the diabetics with one or no copies of allele 2 developed PDR as shown in Figure 1 and Table 1 (above)

30 Genotypes were analyzed for relationship to the survival time from diagnosis of diabetes to treatment for maculopathy, with the following findings. Diabetics with at

- 27 -

least three copies of the less frequent allele (allele 2) at the combined loci for IL-1A (-889 locus) and IL-1B (-511 locus) showed significantly more and earlier maculopathy than individuals with less than three copies of allele 2 as shown in Figure 2 and Table 2A (Odds Ratio 3.52). Removing patients who had an IL-1RN 2,2 genotype increased the Odds Ratio to 4.0 (Table 2B) (above).

The present invention therefore provides a method of identifying diabetic patients at risk for sight-threatening retinopathy to allow early treatment.

Throughout this application various publications and patents are referenced. Full citations for the referenced publications and patents not included herein above are listed below. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

20

### TABLE 3 REFERENCES

Adamis et al., "Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy" *Am. J. Ophthalmol.*, 118(4):445-50 (Oct. 15, 1994).

Aiello et al., "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders" *NEJM*, 331:(22):1480-7 (Dec. 1, 1994).

30

- 28 -

Basic and Clinical Immunology, 8th Ed. eds Stites, Terr & Parslow, Chapter 9, pgs 105-123.

5 Blakemore et al., "Interleukin-1 receptor antagonist gene polymorphism as a severity factor in systemic lupus erythematosus" *Arthritis and Rheumatism* 37(9):1380-1385 (1994).

Blakemore et al., "Interleukin-1 receptor antagonist allele (IL1RN\*2) associated with nephropathy in diabetes mellitus" *Human Genetics* 97:369-374 (1996).

10

The Center for Disease Control and Prevention: "National Diabetes Fact sheet" November 3, 1995.

15 Clark et al., "Genomic sequence for human prointerleukin 1 beta: possible evolution from a reverse transcribed prointerleukin 1 alpha gene" *Nucl Acids Res* 14:7897-7914 (1986) [published erratum appears in *Nucleic Acids Res* 15(2):868 (1987).

Clay et al., "Interleukin-1 receptor antagonist gene polymorphism association with lichen sclerosis" *Human Genetics*, 94:407 (1994).

20

Cork et al., "Psoriasis and interleukin-1. A translation." *Journal of the Royal College of Physicians of London*, 27:366 (Abstract) (1993).

25 de Giovine et al., "Single base polymorphism at -511 in the human interleukin-1 $\beta$  gene (IL10)" *Human Molecular Genetics* 1, No. 6:450 (1992).

Dinarelli, "Interleukin-1 and Interleukin-1 antagonism" *Blood*, 77:1627 (1991).

30 DRS Report No. 7, "A modification of the Airlee House classification of diabetic retinopathy" The Diabetic Retinopathy Research Group, *Invest. Ophthalmol. Vis. Sci.*, 21:210-26 (1981).

- 29 -

DRS Report Number 8, "Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings" (1981)

Duff, "Cytokines and anti-cytokines" *Br. J. Rheumatol* 32 (Suppl 1):15-20 (1993).

5

ETDRS Number 1, "Photocoagulation for diabetic macular edema" Early Treatment Diabetic Retinopathy Study Research Group, *Arch Ophthalmol* 103:1796-1806 (1985).

- 10 ETDRS No. 9, "Early photocoagulation for diabetic retinopathy" Early Treatment Diabetic Retinopathy Study Research Group, *Ophthalmology*, 98:766-785 (1991).

ETDRS Number 12, "Fundus photographic risk factors for progression of diabetic retinopathy Early Treatment Diabetic Retinopathy Study Research Group,

- 15 *Ophthalmology* 98:823-833 (1991).

Franks, et al., "Cytokines in human intraocular inflammation" *Current Eye Research* 11(suppl):187-91 (1992).

- 20 Furutani et al., "Complete nucleotide sequence of the gene for human interleukin 1 alpha" *Nucl Acids Res* 14:3167-3179 (1986).

Hu et al., "Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies" *Inflammation* 18(1):45-58 (1994).

25

Hu and Fan, "Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat" *Inflammation* 19(1):39-54 (1995).

- Klein et al., "The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-  
30 year incidence and progression of diabetic retinopathy [see comments]. Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical school,

- 30 -

Madison. Arch Ophthalmol 112(9):1217-1228 (1994).

Ko, et al., "An (A-C)<sub>n</sub> Dinucleotide Repeat Polymorphic Marker at the 5' End of the Aldose Reductase Gene Is Associated With Early-Onset Diabetic Retinopathy in  
5 NIDDM Patients" Diabetes 44:727-732 (1995).

Koyama et al., "Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet-derived growth factor" *J. Cell Physiol.*, 158(1):1-6 (Jan. 1994).

10

Lowe et al., "Regulation of growth factor mRNA levels in the eyes of diabetic rats" *Metabolism*, 44(8):1038 (1995).

Malecaze et al., "Detection of vascular endothelial growth factor messenger RNA and  
15 vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol., 112(11):1476-82 (Nov. 1994).

Mansfield et al., "Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin 1 receptor antagonist" *Gastroenterology* 106:637-  
20 642 (1994).

McDowell et al., "A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism" *Arthritis & Rheumatism* 38:221-228 (1995).

25 Mandrup-Poulsen et al., "Involvement of interleukin-1 and interleukin-1 antagonist in pancreatic  $\beta$ -cell destruction in insulin-dependent diabetes mellitus" *Cytokine*, 5:185-191 (1993).

McGuire et al., "Variation in the TNF- $\alpha$  promoter region associated with susceptibility  
30 to cerebral malarial" *Nature* 371:508-511 (1994).

- 31 -

Michelson, 1940 [need citation]

Murata et al., "Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels" *Ophthalmic Res.*, 27(1):48-52 (1995).

5

Nedospasov et al., "Tandem arrangement of genes coding for TNF $\alpha$  and lymphotoxin (TNF $\beta$ ) in the human genome" *Cold Spring Harbor Symp Quant Biol* 60:611-624 (1986).

10 Nicklin et al., "A physical map of the region encompassing the human interleukin-1 $\beta$ , and interleukin-1 receptor antagonist genes" *Genomics*, 19:382.9 (1994).

Pe'er et al., "Hypoxia-induced expression vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases" *Lab. Invest.*, 72(6):638-45 (June, 1995).

15

Pfeiffer, "Vascular endothelial growth factor in the aqueous humor in diabetic retinopathy and other diseases of the retina" *Dtsch Med Wochenschr*, 120(42):1453 (Oct. 20, 1995).

20

Pfeiffer and Schatz, "Diabetic microvascular complications and growth factors" *Exp. Clin. Endocrinol. Diabetes*, 103(1):7-14 (1995).

Pociot et al., "A TaqI polymorphism in the human interleukin-1 $\beta$  (IL-1 $\beta$ ) gene correlates with IL-1 $\beta$  secretion *in vitro*" *Eur. J. Clin. Invest.*, 22:396-402 (1992).

25

Seaquist et al., "Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy" *NEJM*, 320:1161 (1989).

McGuire et al.: "Variation in the TNF- $\alpha$  promoter region associated with susceptibility to cerebral malarial, *Nature* 371:508-511 (1994).

30

- 32 -

Tarlow et al., "Severity of Alopecia Areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene" *Journal of Investigative Dermatology*, 103:287 (1994).

- 5 Todd, "Genetic control of auto immunity in Type 1 diabetes" *Immunology Today*, 11:122 (1990).

Verjans *et al.*, "Polymorphism of the tumor necrosis factor region in relation to disease: An overview" *Rheum Dis Clin North Am* 18:177-186 (1992).

10

Woolf, B., "Estimating the relationship between blood groups and disease" *Annals of Human Genetics* 19:251-253 (1955).



**CLAIMS:**

1. A kit for the identification of a diabetic patient's genetic polymorphism pattern at IL-1A, IL-1B(-511), and IL-1RN associated with increased risk of sight-threatening retinopathy, said kit comprising:
  - (a) DNA sample collecting means, and
  - (b) means for determining a genetic polymorphism pattern for IL-1A(-889), IL-1B(-511), and IL-1RN.
2. A kit according to claim 1, wherein the means for determining genetic polymorphism pattern comprises at least one polymerase chain reaction (PCR) primer wherein the PCR primer is selected from:  
5'AAG CTT GTT CTA CCA CCT GAA CTA GGC 3' (SEQ ID No:1);  
5'GTA CCT TCC GAG TAT ACA TT 3' (SEQ ID NO:2);  
5'TGG CAT TGA TCT GGT TCA TC 3' (SEQ ID NO:3);  
5'GTT TAG GAA TCT TCC CAC TT 3' (SEQ ID NO:4);  
5'CTCAGCAACACTCCTAT 3' (SEQ ID NO:5);  
5'TCCTGGTCTGCAGGTAA 3' (SEQ ID No.6);  
5'TGTTCTACCACCTGAACTAGGC 3' (SEQ ID NO:7);  
5'TTACATATGAGCCTTCCATG 3' (SEQ ID No.8);  
5'AAGCTTGTTCTACCACCTGAACTAGGC 3' (SEQ ID No.9); and  
5'TTACATATGAGCCTTCCATG 3' (SEQ ID No.10).
3. A kit according to claim 1 or 2, wherein the means for determining the genetic polymorphism pattern include restriction enzyme digestion with restriction enzymes *NcoI*, *AvaI*, and *Bsu36I*.
4. A method of predicting increased risk of sight-threatening diabetic retinopathy, comprising the steps of:

- (a) identifying in isolated genomic DNA from a sample previously taken from a diabetic patient a genetic polymorphism pattern for the genes IL-1A, IL-1B and IL-1RN;
  - (b) comparing the identified pattern to control patterns of known polymorphisms; and
  - (c) identifying diabetic patients expressing a genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy.
5. A method according to claim 4, wherein said step for identifying in the DNA a genetic polymorphism pattern for IL-1A, IL-1B and IL-1RN comprises amplification of target DNA sequences with a polymerase chain reaction (PCR) and at least one PCR primer, wherein the PCR primer is selected from the group consisting of:
- |  |                    |
|--|--------------------|
| 5'AAG CTT GTT CTA CCA CCT GAA CTA GGC 3' | (SEQ ID No.1);     |
| 5'GTA CCT TCC GAG TAT ACA TT 3'          | (SEQ ID NO:2);     |
| 5'TGG CAT TGA TCT GGT TCA TC 3'          | (SEQ ID NO:3);     |
| 5'GTT TAG GAA TCT TCC CAC TT 3'          | (SEQ ID NO:4);     |
| 5'CTCAGCAACACTCCTAT 3'                   | (SEQ ID NO:5);     |
| 5'TCCTGGTCTGCAGGTAA 3'                   | (SEQ ID NO:6);     |
| 5'TGTTCTACCACCTGAACTAGGC 3'              | (SEQ ID NO:7);     |
| 5'TTACATATGAGCCTTCCATG 3'                | (SEQ ID NO:8);     |
| 5'AAGCTTGTTCTACCACCTGAACTAGGC 3'         | (SEQ:ID NO:9); and |
| 5'TTACATATGAGCCTTCCATG 3'                | (SEQ ID No.10).    |
6. A method according to claim 4 or 5, wherein said step for identifying in the DNA a genetic polymorphism pattern for genes IL-1A, IL-1B and IL-1RN comprises restriction enzyme digestion with restriction enzymes *NcoI*, *AvaI*, and *Bsu36I*.

7. A method according to any of claims 4 to 6, wherein the DNA genetic polymorphism pattern associated with increased risk of clinically-significant macular edema comprises the presence at the combined loci of IL-1A plus IL-1B of at least three copies of the rarer allele for each loci (allele 2) between the two loci.
8. A method according to any of claims 4 to 7, wherein the DNA genetic polymorphism pattern associated with decreased risk of proliferative diabetic retinopathy comprises the presence of the genotype IL-1RN 2,2.
9. A method for predicting risk of sight-threatening diabetic retinopathy, comprising the steps of:
  - (a) identifying in isolated genomic DNA from a sample previously obtained from a diabetic patient a genetic polymorphism pattern for genes IL-1A, IL-1B and IL-1RN;
  - (b) identifying in the DNA a genetic polymorphism pattern for other genes associated with sight-threatening diabetic retinopathy;
  - (c) determining the number of polymorphisms carried by the diabetic patient that are associated with sight-threatening diabetic retinopathy risk, and identifying diabetic patients expressing a multiple genetic polymorphism pattern associated with risk of sight-threatening diabetic retinopathy.

FIG. 1





FIG. 2



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/02790

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MANSFIELD J C ET AL.: "Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist" GASTROENTEROLOGY, vol. 106, 1994, pages 637-642, XP002053011 cited in the application see the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

**\* Special categories of cited documents :**

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 January 1998

Date of mailing of the international search report

13/02/1998

Name and mailing address of the ISA

European Patent Office, P. B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/02790

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KO B C B ET AL.: "An (A-C) <sub>n</sub> dinucleotide repeat polymorphic marker at the 5'End of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients" DIABETES, vol. 44, 1995, pages 727-732, XP002053012 cited in the application see the whole document -----	1-9
P,X	RICHARDSON P S R ET AL.: "Interleukin-1 gene polymorphisms are associated with sight-threatening diabetic retinopathy" INVESTIGATIVE OPHTHALMOLOGY, vol. 38, no. 4, 1997, page 3714 XP002053013 see the whole document -----	1-9